Publicaciones en las que colabora con MARIA BEGOÑA VILLAR CHEDA (14)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

2022

  1. Angiotensin Type-1 Receptor Inhibition Reduces NLRP3 Inflammasome Upregulation Induced by Aging and Neurodegeneration in the Substantia Nigra of Male Rodents and Primary Mesencephalic Cultures

    Antioxidants, Vol. 11, Núm. 2

2021

  1. The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

    Progress in Neurobiology, Vol. 199

2017

  1. Insulin-like growth factor-1 and neuroinflammation

    Frontiers in Aging Neuroscience

2015

  1. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death

    Neuropharmacology, Vol. 85, pp. 1-8

2013

  1. Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

    Movement Disorders, Vol. 28, Núm. 10, pp. 1337-1342

2012

  1. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

    Neurobiology of Aging, Vol. 33, Núm. 1, pp. 204.e1-204.e11

  2. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

    American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244

  3. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: Role of the brain angiotensin system

    Brain, Vol. 135, Núm. 1, pp. 124-138

  4. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

    Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279

2011

  1. Aging, angiotensin system and dopaminergic degeneration in the substantia nigra

    Aging and Disease, Vol. 2, Núm. 3, pp. 257-274

2010

  1. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease

    Experimental Neurology, Vol. 224, Núm. 2, pp. 517-526

2009

  1. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease

    Journal of Cerebral Blood Flow and Metabolism, Vol. 29, Núm. 2, pp. 230-234